LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

171.14 -4.35

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

171

Max

178.68

Belangrijke statistieken

By Trading Economics

Inkomsten

182M

514M

Verkoop

264M

4.4B

K/W

Sectorgemiddelde

22.803

66.845

Winstmarge

11.778

Werknemers

93,000

EBITDA

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.61% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-9B

30B

Vorige openingsprijs

175.49

Vorige sluitingsprijs

171.14

Nieuwssentiment

By Acuity

42%

58%

145 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mrt 2026, 20:38 UTC

Winsten

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mrt 2026, 23:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

10 mrt 2026, 23:57 UTC

Marktinformatie

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mrt 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mrt 2026, 23:35 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mrt 2026, 23:06 UTC

Winsten

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mrt 2026, 22:51 UTC

Belangrijke Nieuwsgebeurtenissen

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mrt 2026, 21:21 UTC

Winsten

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mrt 2026, 21:15 UTC

Winsten

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mrt 2026, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mrt 2026, 21:14 UTC

Winsten

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mrt 2026, 21:13 UTC

Winsten

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mrt 2026, 21:12 UTC

Winsten

Franco-Nevada 4Q Rev $597.3M >FNV

10 mrt 2026, 21:12 UTC

Winsten

Franco-Nevada 4Q EPS $1.90

10 mrt 2026, 20:57 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

10 mrt 2026, 20:44 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:34 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

10 mrt 2026, 20:34 UTC

Marktinformatie
Winsten

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mrt 2026, 20:23 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:16 UTC

Winsten

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mrt 2026, 20:14 UTC

Winsten

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mrt 2026, 20:14 UTC

Winsten

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mrt 2026, 20:13 UTC

Winsten

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mrt 2026, 20:12 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

28.61% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 229.64 USD  28.61%

Hoogste 256 USD

Laagste 200 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

15

Buy

2

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

145 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat